160 related articles for article (PubMed ID: 8745664)
1. Homoharringtonine: an effective new natural product in cancer chemotherapy.
Zhou DC; Zittoun R; Marie JP
Bull Cancer; 1995 Dec; 82(12):987-95. PubMed ID: 8745664
[TBL] [Abstract][Full Text] [Related]
2. Homoharringtonine in patients with myelodysplastic syndrome (MDS) and MDS evolving to acute myeloid leukemia.
Feldman EJ; Seiter KP; Ahmed T; Baskind P; Arlin ZA
Leukemia; 1996 Jan; 10(1):40-2. PubMed ID: 8558935
[TBL] [Abstract][Full Text] [Related]
3. MDR-related P170-glycoprotein modulates cytotoxic activity of homoharringtonine.
Russo D; Michelutti A; Melli C; Damiani D; Michieli MG; Candoni A; Zhou DC; Marie JP; Zittoun R; Baccarani M
Leukemia; 1995 Mar; 9(3):513-6. PubMed ID: 7885049
[TBL] [Abstract][Full Text] [Related]
4. Homoharringtonine inhibits the AKT pathway and induces in vitro and in vivo cytotoxicity in human multiple myeloma cells.
Meng H; Yang C; Jin J; Zhou Y; Qian W
Leuk Lymphoma; 2008 Oct; 49(10):1954-62. PubMed ID: 18949618
[TBL] [Abstract][Full Text] [Related]
5. Homoharringtonine: history, current research, and future direction.
Kantarjian HM; Talpaz M; Santini V; Murgo A; Cheson B; O'Brien SM
Cancer; 2001 Sep; 92(6):1591-605. PubMed ID: 11745238
[TBL] [Abstract][Full Text] [Related]
6. [Research Progress of Homoharringtonine Effect on IM-resistant Chronic Myelogenous Leukemia -Review].
Wang Q; Li YF
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2017 Apr; 25(2):596-599. PubMed ID: 28446318
[TBL] [Abstract][Full Text] [Related]
7. Molecular modes of action of cephalotaxine and homoharringtonine from the coniferous tree Cephalotaxus hainanensis in human tumor cell lines.
Efferth T; Sauerbrey A; Halatsch ME; Ross DD; Gebhart E
Naunyn Schmiedebergs Arch Pharmacol; 2003 Jan; 367(1):56-67. PubMed ID: 12616342
[TBL] [Abstract][Full Text] [Related]
8. Sequential emergence of MRP- and MDR1-gene over-expression as well as MDR1-gene translocation in homoharringtonine-selected K562 human leukemia cell lines.
Zhou DC; Ramond S; Viguie F; Faussat AM; Zittoun R; Marie JP
Int J Cancer; 1996 Jan; 65(3):365-71. PubMed ID: 8575859
[TBL] [Abstract][Full Text] [Related]
9. A phase II study of Homoharringtonine for the treatment of children with refractory or recurrent acute myelogenous leukemia: a pediatric oncology group study.
Bell BA; Chang MN; Weinstein HJ
Med Pediatr Oncol; 2001 Aug; 37(2):103-7. PubMed ID: 11496347
[TBL] [Abstract][Full Text] [Related]
10. Metabolism of homoharringtonine, a cytotoxic component of the evergreen plant Cephalotaxus harringtonia.
Ni D; Ho DH; Vijjeswarapu M; Felix E; Rhea PR; Newman RA
J Exp Ther Oncol; 2003; 3(1):47-52. PubMed ID: 12724858
[TBL] [Abstract][Full Text] [Related]
11. Homoharringtonine binds to and increases myosin-9 in myeloid leukaemia.
Zhang T; Shen S; Zhu Z; Lu S; Yin X; Zheng J; Jin J
Br J Pharmacol; 2016 Jan; 173(1):212-21. PubMed ID: 26448459
[TBL] [Abstract][Full Text] [Related]
12. [Induction of apoptosis by harringtonine and homoharringtonine in HL-60 cells].
Li L; Xia LJ; Jiang C; Han R
Yao Xue Xue Bao; 1994; 29(9):667-72. PubMed ID: 7900538
[TBL] [Abstract][Full Text] [Related]
13. Phase I/II study of subcutaneous homoharringtonine in patients with chronic myeloid leukemia who have failed prior therapy.
Quintás-Cardama A; Kantarjian H; Garcia-Manero G; O'Brien S; Faderl S; Estrov Z; Giles F; Murgo A; Ladie N; Verstovsek S; Cortes J
Cancer; 2007 Jan; 109(2):248-55. PubMed ID: 17154172
[TBL] [Abstract][Full Text] [Related]
14. Homoharringtonine and omacetaxine for myeloid hematological malignancies.
Lü S; Wang J
J Hematol Oncol; 2014 Jan; 7():2. PubMed ID: 24387717
[TBL] [Abstract][Full Text] [Related]
15. MiR-370 sensitizes chronic myeloid leukemia K562 cells to homoharringtonine by targeting Forkhead box M1.
Zhou M; Zeng J; Wang X; Guo Q; Huang T; Shen H; Fu Y; Wang L; Jia J; Chen C
J Transl Med; 2013 Oct; 11():265. PubMed ID: 24148180
[TBL] [Abstract][Full Text] [Related]
16. Omacetaxine mepesuccinate--a semisynthetic formulation of the natural antitumoral alkaloid homoharringtonine, for chronic myelocytic leukemia and other myeloid malignancies.
Quintás-Cardama A; Cortes J
IDrugs; 2008 May; 11(5):356-72. PubMed ID: 18465678
[TBL] [Abstract][Full Text] [Related]
17. [2 homoharringtonine resistant leukemic cell lines (K562 HHT and L1210 HHT): establishment, characterization and mechanisms of action].
Han JL; Yan WW; Qian QJ
Zhonghua Yi Xue Za Zhi; 1994 Jul; 74(7):424-7, 456. PubMed ID: 7987716
[TBL] [Abstract][Full Text] [Related]
18. Induction of apoptosis by homoharringtonine in G1 phase human chronic myeloid leukemic cells.
Mai WY; Lin MF
Chin Med J (Engl); 2005 Mar; 118(6):487-92. PubMed ID: 15788130
[TBL] [Abstract][Full Text] [Related]
19. Homoharringtonine affects the JAK2-STAT5 signal pathway through alteration of protein tyrosine kinase phosphorylation in acute myeloid leukemia cells.
Tong H; Ren Y; Zhang F; Jin J
Eur J Haematol; 2008 Oct; 81(4):259-66. PubMed ID: 18616510
[TBL] [Abstract][Full Text] [Related]
20. Homoharringtonine targets Smad3 and TGF-β pathway to inhibit the proliferation of acute myeloid leukemia cells.
Chen J; Mu Q; Li X; Yin X; Yu M; Jin J; Li C; Zhou Y; Zhou J; Suo S; Lu D; Jin J
Oncotarget; 2017 Jun; 8(25):40318-40326. PubMed ID: 28454099
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
